抗流感病毒药物的研究进展.pdfVIP

药学学报 Acta Pharmaceutica Sinica 2010, 45 (3) : 289299 ·289 · 抗流感病毒药物研究进展 强, 赵庆杰, 熊瑞生, 李剑峰, 沈敬山* ( 中国科学院上海药物研究所, 上海 201203) 摘要: 流感病毒是人类健康的一大威胁。应对流感病毒的主要方式是疫苗和 物治疗。对可能大规模爆发 的流感疫情来讲, 物治疗是最好的控制流感病毒传播的手段。目前, 抗流感病毒药物包括已在俄罗斯上市的盐 酸阿比朵尔和美国FDA 批准的4 个抗流感病毒药物, 后者根据作用机制的不同分为M2 离子通道蛋白抑制 和 神经氨酸酶 (NA) 抑制 。其中, NA 抑制 根据结构又可分为唾液酸类似物、苯甲酸衍生物、环己烯衍生物、 环戊烷衍生物、吡咯烷衍生物及天然提取物 6 大类。本文简要介绍了上述各类已上市和临床在研药物的最新研 究进展。 关键词: 抗流感药物; M2 离子通道蛋白抑制 ; 盐酸阿比朵尔; 神经氨酸酶抑制 中图分类号: R916 文献标识码:A 文章编号: 05 13-4870 (2010) 03-0289-11 Research progress of anti-influenza virus agents * ZHANG Qiang, ZHAO Qing-ji e, XIONG Rui-sheng, LI Jian-feng, SHEN Jing-shan (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) Abstract: Influenza is a maj or threat to millions of people worldwide. Vaccines and antiviral agents are two main options available to reduce the impact of the influenza virus, while anti-influenza agents are the most effective means to prevent the transmission of the highly contagious virus and to treat the epidemics of disease. At present, four anti-influenza agents have been approved by the FDA for the treatment of influenza, including two M2 protein ion channel inhibitors-amantadine and rimantadine and two neuraminidase inhibitors-zanamivir and oseltamivir. Arbidol hydrochloride, launched in Russia, is a potent inhibitor of influenza virus, too. Neuraminidase inhibitors could be classified generally by structure into six different kinds: sialic acid derivatives, benzoic acid derivati